AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1565347 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mg PGE2 gel
Number of subjects: 90
Study 1565347 — intervention group
Group type: COMPARATOR
Intervention: Quartered 20-mg PGE2 suppository
Number of subjects: 90
Study 3974797 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 37
Study 3974797 — intervention group
Group type: COMPARATOR
Intervention: Non-Theophylline
Number of subjects: 37
Study 3974797 — intervention group
Group type: COMPARATOR
Intervention: Fullterm infants
Number of subjects: 37
Study 31062697 — intervention group
Group type: EXPERIMENTAL
Intervention: MiStent
Number of subjects: 36
Study 31062697 — intervention group
Group type: COMPARATOR
Intervention: XIENCE
Number of subjects: 36
Study 31876741 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel and lobaplatin (DL)
Number of subjects: 43
Study 31876741 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel and gemcitabine (DG)
Number of subjects: 43
Study 29621064 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with SCD‐SS
Number of subjects: 44
Study 26282827 — intervention group
Group type: EXPERIMENTAL
Intervention: New algorithms for Masimo pulse oximeters
Number of subjects: 257
Study 26282827 — intervention group
Group type: COMPARATOR
Intervention: Original Masimo oximeter software
Number of subjects: 257
Study 25142262 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentivised case finding for depression using two standard screening questions
Number of subjects: 140237
Study 25142262 — intervention group
Group type: COMPARATOR
Intervention: Non-targeted patients (control group)
Number of subjects: 140237
Study 25142262 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentivised case finding for depression
Number of subjects: 140237
Study 22492381 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum diets with different glycemic indexes and contents of dietary protein
Number of subjects: 742
Study 19816213 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy drink + exercise (EX-A)
Number of subjects: 38
Study 19816213 — intervention group
Group type: COMPARATOR
Intervention: Placebo + exercise (EX-B)
Number of subjects: 38
Study 19816213 — intervention group
Group type: COMPARATOR
Intervention: Energy drink (NEX-A)
Number of subjects: 38
Study 19816213 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NEX-B)
Number of subjects: 38
Study 18822838 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture + tabletop exercise
Number of subjects: 85
Study 18822838 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture only
Number of subjects: 85
Study 18822838 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 85
Study 15857078 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + AZM
Number of subjects: 31
Study 15857078 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 31
Study 12091845 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (400 microg) nebulization, repeated every 2 hours until potassium level fell below 5 mmol/L (maximum 12 doses)
Number of subjects: 19
Study 12091845 — intervention group
Group type: COMPARATOR
Intervention: Saline nebulization (placebo)
Number of subjects: 19
Study 12091845 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (400 microg) nebulization, repeated every 2 hours
Number of subjects: 19
Study 10890262 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 2% ophthalmic solution BID
Number of subjects: 268
Study 10890262 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine 60-mg tablets BID
Number of subjects: 268
Study 10890262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study 10890262 — intervention group
Group type: COMPARATOR
Intervention: Nedocromil sodium, Terfenadine, Placebo
Number of subjects: 268
Study 7724098 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal prostaglandin E2 (PGE2) suppositories
Number of subjects: 51
Study 7724098 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular 15-methyl-prostaglandin F2 alpha (15M-PGF2 alpha)
Number of subjects: 51
Study 1776748 — intervention group
Group type: EXPERIMENTAL
Intervention: HP 128 (adrenergic/cholinergic agent) administered for 10 days
Number of subjects: 0
Study 1776748 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 6125918 — intervention group
Group type: EXPERIMENTAL
Intervention: Clorazepate with phenytoin
Number of subjects: 42
Study 6125918 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbital with phenytoin
Number of subjects: 42
Study 31897956 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) for remission induction and maintenance
Number of subjects: 17
Study 31315114 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (1.5 mg for the first 7 days and 3 mg from day 8 to day 24)
Number of subjects: 70
Study 31315114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 28647744 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported self-help preventive cognitive therapy (S-PCT)
Number of subjects: 248
Study 28647744 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 248
Study 27265548 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (SGAs) - aripiprazole (10-20 mg), olanzapine (10-20 mg), or quetiapine (400-800 mg)
Number of subjects: 149
Study 27265548 — intervention group
Group type: COMPARATOR
Intervention: First-generation antipsychotics (FGAs) - haloperidol (3-6 mg) or flupentixol (6-12 mg)
Number of subjects: 149
Study 27265548 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (SGAs)
Number of subjects: 149
Study 27265548 — intervention group
Group type: COMPARATOR
Intervention: First-generation antipsychotics (FGAs)
Number of subjects: 149
Study 24394682 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention caregivers at 6 months
Number of subjects: 781
Study 24394682 — intervention group
Group type: COMPARATOR
Intervention: Control caregivers at 6 months
Number of subjects: 781
Study 24394682 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention caregivers
Number of subjects: 781
Study 24394682 — intervention group
Group type: COMPARATOR
Intervention: Control caregivers
Number of subjects: 781
Study 24394682 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (frequent feeders)
Number of subjects: 781
Study 21695470 — intervention group
Group type: EXPERIMENTAL
Intervention: Divergent thinking
Number of subjects: 0
Study 21695470 — intervention group
Group type: EXPERIMENTAL
Intervention: Convergent thinking
Number of subjects: 0
Study 19916263 — intervention group
Group type: EXPERIMENTAL
Intervention: 595 nm pulsed dye laser (PDL) with compression handpiece (CHP), 6 J/cm2, 6 msec pulse duration, three monthly treatments
Number of subjects: 10
Study 19916263 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated side)
Number of subjects: 10
Study 19916263 — intervention group
Group type: EXPERIMENTAL
Intervention: 595 nm pulsed dye laser (PDL) with compression handpiece (CHP)
Number of subjects: 10
Study 17265038 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (10 IU IV)
Number of subjects: 0
Study 17265038 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo IV (up to 3 injections at least 5 min apart)
Number of subjects: 0
Study 15591642 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen administered one hour before incision (PRE group)
Number of subjects: 60
Study 15591642 — intervention group
Group type: COMPARATOR
Intervention: Ketoprofen administered immediately after surgery (POST group)
Number of subjects: 60
Study 15591642 — intervention group
Group type: EXPERIMENTAL
Intervention: NCA (Nurse Controlled Analgesia) for postoperative analgesia
Number of subjects: 60
Study 11198531 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI study at baseline and completion of the study
Number of subjects: 105
Study 11198531 — intervention group
Group type: COMPARATOR
Intervention: Clinical score measures
Number of subjects: 105
Study 10518857 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver zeolite (SZ) mouthrinse at a concentration of 3% (w/w), rinsed twice a day for five days
Number of subjects: 11
Study 10518857 — intervention group
Group type: COMPARATOR
Intervention: Type-A zeolite mouthrinse (placebo), rinsed twice a day for five days
Number of subjects: 11
Study 8129004 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 400 mg of sparfloxacin
Number of subjects: 36
Study 8129004 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple daily oral doses totaling 1,000 mg of sparfloxacin
Number of subjects: 36
Study 2672425 — intervention group
Group type: EXPERIMENTAL
Intervention: GM1
Number of subjects: 502
Study 2672425 — intervention group
Group type: EXPERIMENTAL
Intervention: GM1 + H
Number of subjects: 502
Study 2672425 — intervention group
Group type: COMPARATOR
Intervention: P
Number of subjects: 502
Study 2672425 — intervention group
Group type: COMPARATOR
Intervention: P + H
Number of subjects: 502
Study 798369 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidarabine
Number of subjects: 315
Study 798369 — intervention group
Group type: COMPARATOR
Intervention: IDU
Number of subjects: 315
Study 31045264 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified MUF (mMUF)
Number of subjects: 91
Study 31045264 — intervention group
Group type: COMPARATOR
Intervention: Traditional MUF (tMUF)
Number of subjects: 91
Study 28814664 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (low-fixed-dose)
Number of subjects: 30
Study 28814664 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (dose-escalating)
Number of subjects: 30
Study 28814664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 25872773 — intervention group
Group type: EXPERIMENTAL
Intervention: Cascade intervention (online cognitive-behavioural therapy)
Number of subjects: 120
Study 25872773 — intervention group
Group type: COMPARATOR
Intervention: Peer-support group control
Number of subjects: 120
Study 25872773 — intervention group
Group type: COMPARATOR
Intervention: 6-month waitlist control
Number of subjects: 120
Study 23790995 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching Boys Into Men program
Number of subjects: 1513
Study 23790995 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1513
Study 22123970 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support from female partner or close female friend during preparation for a stressful task
Number of subjects: 194
Study 22123970 — intervention group
Group type: COMPARATOR
Intervention: No social support during preparation for a stressful task
Number of subjects: 194
Study 19517694 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusion (AI)
Number of subjects: 150
Study 19517694 — intervention group
Group type: COMPARATOR
Intervention: Control (no amnioinfusion)
Number of subjects: 150
Study 17425628 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg taken 15 min before a high-fat meal (fed)
Number of subjects: 0
Study 17425628 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg taken 4 hours before a non-high-fat meal (fasting)
Number of subjects: 0
Study 15206668 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (30 mg)
Number of subjects: 0
Study 15206668 — intervention group
Group type: COMPARATOR
Intervention: Racemic citalopram (60 mg)
Number of subjects: 0
Study 15206668 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg)
Number of subjects: 0
Study 15206668 — intervention group
Group type: COMPARATOR
Intervention: Racemic citalopram (20 mg)
Number of subjects: 0
Study 11847728 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-type PEG tube
Number of subjects: 0
Study 11847728 — intervention group
Group type: COMPARATOR
Intervention: Non-balloon-type PEG tube
Number of subjects: 0
Study 11847728 — intervention group
Group type: COMPARATOR
Intervention: Both types of PEG tubes
Number of subjects: 0
Study 10023285 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular ketorolac 5 mg
Number of subjects: 60
Study 10023285 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ketorolac 10 mg
Number of subjects: 60
Study 8163781 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg diphenhydramine
Number of subjects: 24
Study 8163781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3360541 — intervention group
Group type: EXPERIMENTAL
Intervention: Trampoline exercise program (maximum 109 min/week for 8 weeks)
Number of subjects: 8
Study 3360541 — intervention group
Group type: EXPERIMENTAL
Intervention: Trampoline exercise program
Number of subjects: 8
Study 3360541 — intervention group
Group type: COMPARATOR
Intervention: Control group (no trampoline exercise)
Number of subjects: 8
Study 31618678 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 days of oral flucloxacillin
Number of subjects: 151
Study 31618678 — intervention group
Group type: COMPARATOR
Intervention: 12 days of antibiotic therapy (intravenous flucloxacillin followed by placebo)
Number of subjects: 151
Study 31618678 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified cure assessment for 6 days of therapy
Number of subjects: 151
Study 31618678 — intervention group
Group type: COMPARATOR
Intervention: Modified cure assessment for 12 days of therapy
Number of subjects: 151
Study 30551654 — intervention group
Group type: EXPERIMENTAL
Intervention: L. rhamnosus 19070‐2 and L. reuteri 12246 with 250 × 10⁶ CFU, 3.33 mg of fructooligosaccharide, and 200 IU of vitamin D₃ (probiotic group)
Number of subjects: 168
Study 30551654 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D₃ only (control group)
Number of subjects: 168
Study 30551654 — intervention group
Group type: EXPERIMENTAL
Intervention: L. rhamnosus 19070‐2 and L. reuteri 12246 (probiotic group)
Number of subjects: 168
Study 27798661 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative treatments for cancer
Number of subjects: 17
Study 24916558 — intervention group
Group type: COMPARATOR
Intervention: Preworkout supplement (SUP) containing caffeine, creatine, β-alanine, amino acids, and B vitamins, ingested daily for 28 days.
Number of subjects: 0
Study 24916558 — intervention group
Group type: COMPARATOR
Intervention: Preworkout supplement (SUP)
Number of subjects: 0
Study 23149797 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuously variable dose rate (CVDR)
Number of subjects: 10
Study 23149797 — intervention group
Group type: COMPARATOR
Intervention: Fixed binned dose rates (BDR)
Number of subjects: 10
Study 20855397 — intervention group
Group type: EXPERIMENTAL
Intervention: Day care management with antibiotic treatment, feeding, and supportive care from 8:00 am to 5:00 pm.
Number of subjects: 360
Study 20855397 — intervention group
Group type: COMPARATOR
Intervention: Hospital care management with similar 24-hour treatment.
Number of subjects: 360
Study 20855397 — intervention group
Group type: EXPERIMENTAL
Intervention: Day care management.
Number of subjects: 360
Study 20855397 — intervention group
Group type: COMPARATOR
Intervention: Hospital care management.
Number of subjects: 360
Study 18815018 — intervention group
Group type: EXPERIMENTAL
Intervention: Willow bark extract
Number of subjects: 90
Study 18815018 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 90
Study 18815018 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 90
Study 15739554 — intervention group
Group type: EXPERIMENTAL
Intervention: IL13-PE38QQR before and after tumor resection
Number of subjects: 14
Study 15739554 — intervention group
Group type: EXPERIMENTAL
Intervention: IL13-PE38QQR after tumor resection
Number of subjects: 14
Study 12870164 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Caiapo (4 g/d)
Number of subjects: 18
Study 12870164 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Caiapo (2 g/d)
Number of subjects: 18
Study 12870164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12870164 — intervention group
Group type: EXPERIMENTAL
Intervention: Caiapo (both doses)
Number of subjects: 18
Study 11285043 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (2 mg oestradiol valerate for the first 3 months, with the addition of 10 mg medroxyprogesterone for 10 days every third month thereafter)
Number of subjects: 51
Study 11285043 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 51
Study 11285043 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 51
Study 9109825 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-solution rinse
Number of subjects: 13
Study 9109825 — intervention group
Group type: COMPARATOR
Intervention: NaF rinse (12 mmol/L, 228 ppm)
Number of subjects: 13
Study 8510705 — intervention group
Group type: EXPERIMENTAL
Intervention: White men
Number of subjects: 2181
Study 8510705 — intervention group
Group type: EXPERIMENTAL
Intervention: Black men
Number of subjects: 2181
Study 8510705 — intervention group
Group type: EXPERIMENTAL
Intervention: White women
Number of subjects: 2181
Study 8510705 — intervention group
Group type: EXPERIMENTAL
Intervention: Black women
Number of subjects: 2181
Study 8510705 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 2181
Study 3105364 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed Unit of Instruction (PUI) on infection control principles
Number of subjects: 40
Study 3105364 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PUI)
Number of subjects: 40
Study 29870595 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 2 mg
Number of subjects: 0
Study 29870595 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 4 mg
Number of subjects: 0
Study 29870595 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 6 mg
Number of subjects: 0
Study 29870595 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel (2-6 mg)
Number of subjects: 0
Study 25977313 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (D1-like receptor agonist) during high NaCl diet
Number of subjects: 7
Study 25977313 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (D1-like receptor agonist) during low NaCl diet
Number of subjects: 7
Study 25977313 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam with enalapril (ACE inhibitor) during low NaCl diet
Number of subjects: 7
Study 25977313 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam during high NaCl diet
Number of subjects: 7
Study 25977313 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam during low NaCl diet
Number of subjects: 7
Study 25687147 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose plus radiant warmth
Number of subjects: 29
Study 25687147 — intervention group
Group type: COMPARATOR
Intervention: Sucrose alone
Number of subjects: 29
Study 24168259 — intervention group
Group type: EXPERIMENTAL
Intervention: HBIG + recombinant HBV vaccine
Number of subjects: 259
Study 24168259 — intervention group
Group type: COMPARATOR
Intervention: Placebo + recombinant HBV vaccine
Number of subjects: 259
Study 24168259 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcomes at 24 months
Number of subjects: 259
Study 19940005 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2/neu overexpression (3+ protein expression)
Number of subjects: 150
Study 19940005 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2/neu overexpression
Number of subjects: 150
Study 19940005 — intervention group
Group type: EXPERIMENTAL
Intervention: LMVD
Number of subjects: 150
Study 18795988 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/wk testosterone enanthate
Number of subjects: 44
Study 18795988 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/wk testosterone enanthate
Number of subjects: 44
Study 18795988 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg/wk testosterone enanthate
Number of subjects: 44
Study 18795988 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/wk testosterone enanthate
Number of subjects: 44
Study 18795988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 16374438 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic lock solution (cefazolin 10 mg/ml, gentamicin 5 mg/ml, heparin 1000 U/ml)
Number of subjects: 120
Study 16374438 — intervention group
Group type: COMPARATOR
Intervention: Heparin lock solution (heparin 1000 U/ml)
Number of subjects: 120
Study 16374438 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic lock solution
Number of subjects: 120
Study 16374438 — intervention group
Group type: COMPARATOR
Intervention: Heparin lock solution
Number of subjects: 120
Study 12749507 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg orally once daily
Number of subjects: 14
Study 12749507 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 67 mg orally TID
Number of subjects: 14
Study 12749507 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin + Fenofibrate (dosed as above)
Number of subjects: 14
Study 10768324 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA 0.05%
Number of subjects: 877
Study 10768324 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA 0.1%
Number of subjects: 877
Study 10768324 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 877
Study 8807105 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic BMT (alloBMT)
Number of subjects: 730
Study 8807105 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy
Number of subjects: 730
Study 31187226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryptosporidium parvum infection in calves with diarrhea
Number of subjects: 1073
Study 31187226 — intervention group
Group type: EXPERIMENTAL
Intervention: GP60 subtyping of C. parvum isolates
Number of subjects: 1073
Study 30260897 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical impedance tomography-guided PEEP
Number of subjects: 40
Study 30260897 — intervention group
Group type: COMPARATOR
Intervention: Institutional PEEP (4 cm H2O)
Number of subjects: 40
Study 27028913 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (Vivitrol) for 24 weeks
Number of subjects: 308
Study 27028913 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (brief counseling and referrals for community treatment programs)
Number of subjects: 308
Study 24953333 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m²) plus cisplatin (75 mg/m²) followed by gefitinib maintenance
Number of subjects: 236